Advent International agrees to buy majority stake in NZCR Group
Reuters2026/08/20 06:08- Advent agreed to buy a majority stake in New Zealand Clinical Research Group, a clinical trials and medical research provider in New Zealand and Australia.
- NZCR Group management and clinician shareholders, alongside Waterman Capital, will retain a significant minority holding; financial terms were not disclosed.
- The business operates a clinical research site network across the NZCR, CMAX, Optimal, and Fusion brands.
- Closing is expected in Q4 2026, subject to customary regulatory approvals.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SK Hynix (SKHY.US) "sky-high bonus" distribution plan preliminarily confirmed: 60% in shares, 40% in cash, with an average per capita bonus expected to reach 779 million KRW
According to a source familiar with the matter, South Korean chip giant SK Hynix has reached a preliminary wage agreement to distribute 60% of this year's employee bonuses in the form of company stock, with the remaining 40% to be paid in cash.
Samsung Accelerates Expansion in the US: Texas No. 2 Wafer Plant to Start Construction by Year-End, Equipment Certification Already Initiated
Samsung's North American expansion is advancing rapidly. Although the specifications for the second phase in Texas have not yet been finalized, Samsung is already requiring suppliers to accelerate equipment certification. After securing a major Tesla order and putting the first-phase 2nm production line into operation by the end of this year, the second phase aims for mass production by 2030. Whether Samsung can secure another "super client" in advance will be the key to the timely surge in its production capacity.
Swedish Krona: Hawkish Riksbank stance holds – Commerzbank
Crypto prices
More
